Authors

Analysis of thousands of hospital records from the UK suggests an increased cancer risk for patients with PMR, but only within six months after diagnosis and only for certain malignancies.

Richard F. Loeser, MD

Richard J. Adam, MD

Richard Martin MD

Richard S. Panush, MD

Rita Baron Faust

Rita Baron-Faust

Rita Baron-Faust MPH

Rita Baron-Faust, MPH

Robert A. Pedowitz, MD, PhD

Robert Afra, MD

Robert B. Anderson, MD

Robert B. Uzor, MD

Robert F. Mclain, MD

Determining treatment of lumbar disk protrusion and disk extrusion

17 years ago

Disk herniation is a common spine disorder that has a wide range of presentations and clinical significance.1,2 The potential for recovery varies from patient to patient, depending on the size of the protrusion, the size of the canal, the patient’s age and activity level, and the extent of disk disruption.3

Robert L. Wortmann, MD

Robert M. Szabo, MD, MPH

Robert N. Jamison, PhD

Robert Plenge MD, Phd

Robyn G. Young, MD

Roger Turcotte, MD

Idiopathic Chilblains

14 years ago

Chilblains is usually an idiopathic disorder characterized by red-purple papules, patches, or plaques that develop on the extremities in non-freezing cold or damp conditions, most often on the hands and feet.

Roseda Molina

Roy Altman MD

Russell M. Lafrance, MD

Ryan C. Goodwin, MD

S. Sam Lim, MD

Salahuddin Kazi, MD

Sarada Jaimungal, MBBS

Sebahattin Yurdakul, MD

Sergey Prokhorov, MD

Series editor: Eric Bogner MD

Authors

Is There a Link Between Cancer and Polymyalgia Rheumatica?

Determining treatment of lumbar disk protrusion and disk extrusion

Idiopathic Chilblains

Trending on HCPLive

ACHIEVE-5: Orforglipron Improves Glycemic Control, Weight in T2D on Basal Insulin

Survodutide Shows Fat Mass Loss, Liver Fat Reductions in Patients With Obesity Without T2D

VESALIUS-CV: Evolocumab Reduces Cardiovascular Events in Patients With High-Risk Diabetes

GLP-1 Discontinuation Cuts Chances of Meeting Weight Loss, Glycemic Goals in T2D

ZUPREME-1: Petrelintide Reduces Obesity, Maintains Tolerability in Phase 2 Trial